VOBRIG Drug Patent Profile
Which patents cover Vobrig, and when can generic versions of Vobrig launch?
Vobrig is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in VOBRIG is leuprolide acetate. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vobrig
A generic version of VOBRIG was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VOBRIG?
- What are the global sales for VOBRIG?
- What is Average Wholesale Price for VOBRIG?
Summary for VOBRIG
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | VOBRIG at DailyMed |
US Patents and Regulatory Information for VOBRIG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | VOBRIG | leuprolide acetate | SOLUTION;SUBCUTANEOUS | 213225-001 | Aug 26, 2026 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

